Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection.

Therapeutic Advances in Gastroenterology
Paul Y Kwo

Abstract

Chronic hepatitis C infection is a leading cause of morbidity and mortality worldwide, with hepatitis C related cirrhosis being the most common indication for transplant and a major cause for the increase in hepatocellular carcinoma worldwide. Treatment for hepatitis C has consisted of nonspecific immunomodulatory therapies that stimulate the immune system and inhibit hepatitis C replication. Pegylated (peg-)interferon and ribavirin have been the standard of care with an overall sustained response rate of 40-50% in patients with genotype 1 infection, and 80% in genotype 2 or 3. Recently, direct-acting antiviral agents, including boceprevir, have demonstrated improved sustained response rates in patients with genotype 1 infection when given in combination with interferon and ribavirin. Boceprevir is a structurally novel hepatitis C virus (HCV) nonstructural 3 (NS3) protease inhibitor that has demonstrated robust antiviral activity in HCV replicons. Clinically, in phase II and III trials, boceprevir 800 mg three times daily with peginterferon and ribavirin has led to improved sustained response rates in genotype 1 infection treatment-naive patients, relapsers, partial responders, and null responders. Phase II data have demonstrat...Continue Reading

References

Jun 22, 2000·The Journal of General Virology·R Bartenschlager, V Lohmann
Oct 26, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T PoynardJ Albrecht
Jul 7, 2001·The New England Journal of Medicine·G M Lauer, B D Walker
Nov 5, 2002·Nature Reviews. Drug Discovery·Ralf Bartenschlager
May 28, 2004·The New England Journal of Medicine·Andrew J MuirUNKNOWN Atlantic Coast Hepatitis Treatment Group
Aug 8, 2006·Gastroenterology·Hari S ConjeevaramUNKNOWN Virahep-C Study Group
Dec 8, 2006·The New England Journal of Medicine·Jay H Hoofnagle, Leonard B Seeff
Jun 7, 2007·World Journal of Gastroenterology : WJG·Miriam J Alter
Jun 16, 2007·Gastroenterology·Hashem B El-Serag, K Lenhard Rudolph
Jul 13, 2007·The New England Journal of Medicine·Mitchell L ShiffmanUNKNOWN ACCELERATE Investigators
Jan 16, 2009·The New England Journal of Medicine·Maribel Rodriguez-TorresUNKNOWN Latino Study Group
Nov 17, 2009·Gastroenterology·Peter FerenciUNKNOWN Austrian Hepatitis Study Group
Mar 3, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Moises DiagoDavid R Nelson
Aug 21, 2010·Gastroenterology·Mark S SulkowskiUNKNOWN IDEAL Study Team
Apr 1, 2011·The New England Journal of Medicine·Fred PoordadUNKNOWN SPRINT-2 Investigators

❮ Previous
Next ❯

Citations

Feb 24, 2016·Acta Pharmaceutica Sinica. B·Xingquan Zhang
Aug 11, 2015·Japanese Journal of Infectious Diseases·Dadan Ramadhan ApriyantoHak Hotta
Sep 24, 2016·Expert Opinion on Drug Safety·Mohamed El KassasGamal Esmat

❮ Previous
Next ❯

Methods Mentioned

BETA
phosphotransferase

Clinical Trials Mentioned

NCT00708500

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

Drugs of Today
S A RizzaZ Temesgen
Liver International : Official Journal of the International Association for the Study of the Liver
M MannsM Cornberg
© 2021 Meta ULC. All rights reserved